

Nectar Lifesciences Limited



Ref No. NLL/CS/2022-141

June 07, 2022

National Stock Exchange of India Limited
Listing Department,
Exchange Plaza, Bandra Kurla Complex,
Bandra (E), Mumbai 400 051
Symbol: NECLIFE

BSE Limited
Corporate Relationship Department,
P J Towers, Dalal Street,
Mumbai 400 001
Scrip Code: 532649

Sub: Disclosure of Related Party Transactions.

Ref.: SEBI Circular No. SEBI/HO/CFD/CMD1/CIR/P/2021/662 dated November 22, 2021

Dear Sir/Madam,

Pursuant to Compliance with Regulation 23(9) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, as amended and captioned circular, please find enclosed the disclosure on Related Party Transactions for half year period from October 01, 2021 to March 31, 2022.

This is for your information and records.

Yours faithfully,

For **Nectar Lifesciences Limited**

(Anubha)

Company Secretary & Compliance Officer

Encl. As above

| S. No. | Details of the party (listed entity/ subsidiary) entering into the transaction | | Details of the Counterparty | | | Type of related party transactions | Value of the related party transaction as approved by the audit committee | Value of transaction during the reporting period | In case monies are due to either party as a result of the transaction | | Additional disclosure of related party transactions - applicable only in case the related party transaction relates to loans, inter-corporate deposits, advances or investments made or given by the listed entity/ subsidiary. These details need to be disclosed only once, during the reporting period when such transaction was undertaken. | | | Details of the loans, inter-corporate deposits, advances or investments | | | | |
|--------|--|-----|-----------------------------|---|---|---|---|--|---|-----------------|---|------|--------|---|-------------------|--------|--------------------|---|
| | | | | | | | | | | | In case any financial indebtedness is incurred to make or give loans, inter-corporate deposits, advances or investments | | | Nature (loan/ advance/ inter-corporate deposit/ invesment) | Interest Rate (%) | Tenure | Secured/ Unsecured | Purpose for which the funds will be utilized by the ultimate recipient of funds (end-usage) |
| | Name | PAN | Name | PAN | Relationship of the counterparty with the listed entity or its subsidiary | | | | Opening Balance | Closing Balance | Nature of indebtedness (loan/ issuance of debt/ any other etc.) | Cost | Tenure | | | | | |
| 1 | Nectar Lifesciences Limited | | | Mr. Sanjiv Goyal | Chairman & Managing Director | Managerial Remuneration | Note 1 | 99.44 | 8.35 | 15.04 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 2 | Nectar Lifesciences Limited | | | Mr. Dinesh Dua | Executive Director | Managerial Remuneration | Note 1 | 31.43 | 2.72 | 3.87 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 3 | Nectar Lifesciences Limited | | | Mr. Amit Chadah | Chief Executive Officer | Salary to KMP | Note 1 | 37.96 | 3.33 | 3.11 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 4 | Nectar Lifesciences Limited | | | Mr. Sandeep Goel | Chief Financial Officer | Salary to KMP | Note 1 | 12.33 | 1.50 | 1.33 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 5 | Nectar Lifesciences Limited | | | Ms. Anubha | Company Secretary | Salary to KMP | Note 1 | 2.12 | 0.34 | 0.35 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 6 | Nectar Lifesciences Limited | | | Ms. Guljit Sethi | Independent Director | Sitting Fees | Note 1 | 0.45 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 7 | Nectar Lifesciences Limited | | | Mr. Vivek K Sett | Nominee Director | Sitting Fees | Note 1 | 0.40 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 8 | Nectar Lifesciences Limited | | | Mr. Ajay Swaroop | Independent Director | Sitting Fees | Note 1 | 0.40 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 9 | Nectar Lifesciences Limited | | | Dr. Rupinder Tewari | Independent Director | Sitting Fees | Note 1 | 0.55 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 10 | Nectar Lifesciences Limited | | | Dr. Kuldip Kumar Bhasin | Independent Director | Sitting Fees | Note 1 | 0.55 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 11 | Nectar Lifesciences Limited | | | Ms. Meena Verma | Nominee Director | Sitting Fees | Note 1 | 0.40 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 12 | Nectar Lifesciences Limited | | | Nectar Lifesciences Charitable Foundation | Promoter/Director and KMPs have significant Influence | CSR expenditure | Note 1 | 6.77 | - | - | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 13 | Nectar Lifesciences Limited | | | Nectar Lifesciences USA LLC | Wholly owned subsidiary | Purchase/ Sale/ Trade receivables/ Payable etc. | Not Applicable | - | 94.24 | 94.24 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 14 | Nectar Lifesciences Limited | | | Mr. Amit Chadah | Chief Executive Officer | Unsecured Interest free loan given | Not Applicable | - | 30.62 | 30.62 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |
| 15 | Nectar Lifesciences Limited | | | Sanjiv (HUF) | Promoter/Director have significant Influence | Unsecured Interest free loan received | Not Applicable | - | 1,000.00 | 1,000.00 | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | N.A. | |

Note 1. Audit Committee approval has been received on all perpetual transactions for the term of Managerial Remuneration/ Salary to KMPs/ Sitting Fee/ CSR Expenditure- Further approvals from Board / members have been received as per the provisions of the Companies Act, 2013

Note 2. Opening and closing balance are not given where there was no transaction of Investment in subsidiaries during the half year ended March 31, 2022-